Evaxion A/S EVAX 深 滬
等待開盤 10-08 09:30:00 美东时间
3.16
0.000
0.00%
華盛通- 最 高3.25
- 今 開3.16
- 成交量 2.17万股
- 最 低 3.11
- 昨 收 3.16
- 總市值 2850.79万
- 52周最高 8.10
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 2.77
- 委 比 23.95%
- 總股本 902.15万
- 歷史最高 1252.00
- 量 比 0.66
- 振 幅 4.43%
- 歷史最低 2.77
- 每 手 1
- 風險率 1.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Evaxion Expands AI-Immunology Platform into Autoimmune Diseases
Evaxion Biotech ( ($EVAX) ) just unveiled an update. On September 14, 2026, Eva...
09-14 20:35
Analysts’ Top Healthcare Picks: Evaxion Biotech (EVAX), Ultragenyx Pharmaceutical (RARE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-21 19:10
Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript
On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. View the webcast at...
08-20 21:34
Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
08-20 19:31
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform ...
08-20 16:53
Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma
EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platform Glioblastoma is characterized by high mortality rates and significant unmet medical needs. EVX-05...
08-17 20:03
Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026
Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented t...
07-17 19:19
Evaxion To Present New Preclinical Data For Vaccine Candidate EVX-V1 In Poster Session At IHW 2026
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidate Poster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion")...
07-01 20:01
Evaxion Unveils Promising Preclinical Data for AI-Designed AML Vaccine EVX-04
Evaxion Biotech ( ($EVAX) ) has issued an announcement. On June 11, 2026, Evaxi...
06-11 18:28
